Search

NeoGenomics Inc

Atvērts

SektorsVeselības aprūpe

17.09 1.97

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.3

Max

16.88

Galvenie mērījumi

By Trading Economics

Ienākumi

19M

2.2M

Pārdošana

15M

202M

EPS

-0.01

Peļņas marža

1.11

Darbinieki

2,500

EBITDA

19M

19M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+30.94% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 28. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

427M

2.1B

Iepriekšējā atvēršanas cena

15.12

Iepriekšējā slēgšanas cena

17.09

NeoGenomics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. okt. 23:21 UTC

In after-market trading, Neogenomics Inc shares are down significantly, continuing a decline that positions them below the 20-day moving average.

2026. g. 16. okt. 20:02 UTC

Correlated Moves

Neogenomics Inc shares are declining amid a broader market trend, influenced by the sharply lower ARK Genomic Revolution ETF (ARKG) and negative news at Tempus AI.

2026. g. 15. okt. 19:46 UTC

News

NeoGenomics expands partnership with Indica Labs to enhance digital pathology using AI-driven tools, aiming to streamline operations and improve diagnostic capabilities.

2026. g. 14. okt. 20:21 UTC

Neogenomics Inc shares are trading lower in after-market hours, tracking significant declines in major U.S. stock indices amid rising inflation concerns and expectations of a rate hike.

2026. g. 13. okt. 20:02 UTC

Neogenomics Inc is trading higher, having rebounded from earlier weakness, after reaching a notable peak around mid-afternoon on Tuesday.

2026. g. 8. okt. 20:07 UTC

Neogenomics Inc shares are trading modestly higher, recovering from an early drop amid a broader market gain since Wednesday's close.

2026. g. 7. okt. 20:07 UTC

Neogenomics Inc. shares fell sharply, closing well below the 20-day moving average amid overall market declines during Wednesday's trading session.

2026. g. 6. okt. 23:31 UTC

Neogenomics Inc saw a notable increase in after-market trading, moving higher since Tuesday's close, despite being below its 20-day moving average.

2026. g. 5. okt. 23:01 UTC

News

NeoGenomics shares declined in after-market trading following the announcement of a leadership transition and preliminary Q3 revenue expectations of approximately $209 million.

2026. g. 2. okt. 20:07 UTC

Neogenomics Inc is advancing, reflecting a broader market trend with significant gains today, and is higher since Thursday's close.

2026. g. 1. okt. 20:07 UTC

Neogenomics Inc shares fell sharply, closing at their lowest point of the day and marking five consecutive lower daily closes amid ongoing market weakness.

2026. g. 30. sept. 20:31 UTC

Neogenomics Inc shares are higher in after-market trading, reversing four sessions of losses, following positive U.S. GDP growth and strong ADP employment data.

2026. g. 29. sept. 20:07 UTC

Neogenomics Inc shares fell sharply, closing near their lowest point of the day after reversing from an early peak, amid ongoing challenges.

2026. g. 28. sept. 23:11 UTC

Neogenomics Inc. saw a modest increase in after-market trading, reaching its highest cumulative return since Monday and remaining above its 20-day moving average.

2026. g. 25. sept. 22:25 UTC

Neogenomics Inc shares declined in after-market hours following Friday's close, amid broader market weakness due to flat U.S. durable goods orders and low consumer sentiment.

2026. g. 24. sept. 20:02 UTC

Neogenomics Inc is advancing sharply, maintaining a trend of higher daily closes since Wednesday, supported by strength in the broader health care services sector.

2026. g. 22. sept. 20:07 UTC

News

Neogenomics Inc shares fell sharply, declining since Monday's close, despite early session gains and interest in its strategic shift towards precision oncology.

2026. g. 21. sept. 21:21 UTC

Neogenomics Inc is trading modestly lower in after-market hours, declining from an initial high despite being above its 20-day moving average.

2026. g. 17. sept. 20:07 UTC

Correlated Moves

Neogenomics Inc is advancing, supported by gains in the ARK Genomic Revolution ETF and positive broader market trends, marking five consecutive sessions of gains.

2026. g. 15. sept. 20:07 UTC

Neogenomics Inc's shares are higher today, reflecting a notable increase since Monday's close. The stock remains above its 20-day moving average.

2026. g. 14. sept. 23:46 UTC

Neogenomics Inc shares are modestly higher in after-market trading, maintaining a position above its 20-day moving average and near the top of its one-month range.

2026. g. 11. sept. 21:01 UTC

Neogenomics Inc shares declined in after-market trading, coinciding with a significant drop in the Michigan Consumer Sentiment Index. No specific company news was identified.

2026. g. 10. sept. 20:07 UTC

Neogenomics Inc shares are lower today amid a broader market decline and rising Treasury yields, with no specific company news identified.

2026. g. 9. sept. 20:07 UTC

Neogenomics Inc's shares are higher Wednesday, despite an earlier pullback. No specific company news was identified to explain the price movement.

2026. g. 8. sept. 19:26 UTC

Neogenomics Inc shares are higher today, continuing gains since Friday. The stock remains above its 20-day moving average and within its one-month range.

2026. g. 4. sept. 23:20 UTC

Neogenomics Inc shares are higher in after-market trading, reflecting strong performance since Friday's close and positioning above its 20-day moving average.

2026. g. 2. sept. 20:08 UTC

Neogenomics Inc is lower in Wednesday's session, continuing a trend of four consecutive declines. No specific news was identified to explain the move.

2026. g. 1. sept. 20:08 UTC

Neogenomics Inc shares are lower today, continuing a downward trend since Monday. No specific company news was identified to explain the decline.

2026. g. 31. aug. 20:07 UTC

Social Media

Neogenomics Inc shares are lower amid rising interest rate hike expectations following recent economic commentary. Earlier, the stock rebounded from a session high.

2026. g. 28. aug. 20:51 UTC

Neogenomics Inc's shares are higher in after-market hours, moving significantly above their 20-day moving average and near the upper end of their one-month range.

Salīdzinājums

Cenas izmaiņa

NeoGenomics Inc Prognoze

Cenas mērķis

By TipRanks

30.94% augšup

Prognoze 12 mēnešiem

Vidējais 21.5 USD  30.94%

Augstākais 28 USD

Zemākais 19 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi NeoGenomics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

6

Pirkt

2

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
help-icon Live chat